Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression: A 10-Week Randomized Open Study.

Navarro, Víctor; Boulahfa, Ilham; Obach, Amadeu; Jerez, Dídac; Diaz-Ricart, Maribel; Gastó, Cristóbal; Guarch, Joana

Navarro, Víctor; Boulahfa, Ilham; Obach, Amadeu; Jerez, Dídac; Diaz-Ricart, Maribel; Gastó, Cristóbal; Guarch, Joana.

Affiliation

Boulahfa I; Research, Innovation and Teaching Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat (Barcelona).
Jerez D; Department of Hemotherapy and Hemostasis, Hospital Clinic of Barcelona, Biomedical Diagnosis Centre, IDIBAPS, UB, University of Barcelona, Barcelona, Spain.
Diaz-Ricart M; Department of Hemotherapy and Hemostasis, Hospital Clinic of Barcelona, Biomedical Diagnosis Centre, IDIBAPS, UB, University of Barcelona, Barcelona, Spain.

J Clin Psychopharmacol ; 39(1): 63-66, 2019.

Article in En | MEDLINE | ID: mdl-30516574

Subject(s)

Depressive Disorder, Major/drug therapy; Depressive Disorder, Treatment-Resistant/drug therapy; Imipramine/therapeutic use; Mirtazapine/therapeutic use; Venlafaxine Hydrochloride/therapeutic use; Adolescent; Adult; Aged; Antidepressive Agents/therapeutic use; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Major / Depressive Disorder, Treatment-Resistant / Venlafaxine Hydrochloride / Mirtazapine / Imipramine Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Psychopharmacol Year: 2019 Type: Article

Fulltext

XML

PubMed Links

Search on Google